Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
Top Cited Papers
Open Access
- 14 January 2022
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 44, 101262
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council (MC_PC_19076)
- Medical Research Council (MC_UU_12023/23)
- Medical Research Council (MC_UU_00004/04)
- Engineering and Physical Sciences Research Council (EP/R013764/1)
- James B. Pendleton Charitable Trust
- National Institute for Health and Care Research
- NIHR Imperial Biomedical Research Centre
This publication has 31 references indexed in Scilit:
- Alphavirus RNA synthesis and non-structural protein functionsJournal of General Virology, 2015
- Adaptation in the innate immune system and heterologous innate immunityCellular and Molecular Life Sciences, 2014
- Differences in innate immune response between man and mouseCritical Reviews in Immunology, 2014
- Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype CgagVaccine in Healthy HIV-1-Uninfected AdultsClinical and Vaccine Immunology, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteersVaccine, 2009
- The 5′UTR-specific mutation in VEEV TC-83 genome has a strong effect on RNA replication and subgenomic RNA synthesis, but not on translation of the encoded proteinsVirology, 2009
- Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8Science, 2004
- Adsorption-Induced Antigenic Changes and Their Significance in Elisa and Immunological DisordersImmunological Investigations, 1997
- Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccineVaccine, 1996